We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Ros4.5

Rosuvastatin (Crestor) Research

Mostly mechanism / observational

218 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Rosuvastatin (Crestor) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2006–2026 with a typical study size of 1,039 participants.

Based on 218 studies · 23 meta-analyses · 192 RCTs · 111,472 total participants

Confidence

High confidence

By outcome

Cardiovascular events & plaqueIn JUPITER reduced major cardiovascular events ~44% and all-cause mortality ~20% in primary prevention; serial-IVUS trials show coronary plaque regression · Months to years (LDL drop by 2-4 weeks)
Mostly mechanism / observational50 studies
LDL & lipid loweringIn JUPITER reduced major cardiovascular events ~44% and all-cause mortality ~20% in primary prevention; serial-IVUS trials show coronary plaque regression · Months to years (LDL drop by 2-4 weeks)
Mostly mechanism / observational38 studies
Glucose & metabolic
Mostly mechanism / observational19 studies
Safety profile
Mostly mechanism / observational5 studies

Steady research

37 studies in the last 5 years · Latest meta-analysis: 2026

200620162026

1Meta-Analysis2025

Sayehmiri K, Shohani M, Qavam S, Tavan H · Life Sci (2025)

Rosuvastatin (Crestor) Research

Mostly mechanism / observational

Comparing the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL: A systematic review and meta-analysis.

Periodic dosing regimens of atorvastatin and rosuvastatin for dyslipidemia: A systematic review and meta-analysis of randomized controlled trials.

Effect of statins on blood pressure: Analysis on adverse events released by FDA.

Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia.

Locally delivered simvastatin and rosuvastatin in the treatment of chronic periodontitis: A systematic review and meta-analysis.

Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies.

Meta-analysis comparing the effects of rosuvastatin versus atorvastatin on regression of coronary atherosclerotic plaques.

Impact of rosuvastatin versus atorvastatin on coronary atherosclerotic plaque volume - a systematic review and meta-analysis with trial sequential analysis of randomized control trials.

Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis.

Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis.

Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials.

Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials.

Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database.

Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence.

Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis.

Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury.

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.

Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis.

Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis.

Effect of ABCG2 c.421 C> A (rs2231142) single nucleotide polymorphisms on the lipid-modulating efficacy of rosuvastatin: a meta-analysis.